Abstract
Rheumatic disease is characterized by inflammation and endothelial dysfunction, which contribute to accelerated atherosclerosis. Circulating endothelial progenitor cells (EPCs) can restore dysfunctional endothelium and thereby protect against atherosclerotic vascular disease. The number and function of EPCs are, however, affected in rheumatic diseases such as psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and antineutrophil cytoplasmic autoantibody-associated vasculitis. Rheumatic disease is often characterized by decreased numbers, and impaired function, of EPCs, although numbers of these cells might increase during the initial years of systemic sclerosis. Pioneering studies show that EPC dysfunction might be improved with pharmacological treatment. How best to restore EPC function, and whether achieving this aim can prevent long-term cardiovascular complications in rheumatic disease, remain to be established.
Key Points
-
Endothelial progenitor cells (EPCs) can be characterized as monocytic or hemangioblastic, and have diverse origins and functions
-
EPC dysfunction accelerates atherosclerotic cardiovascular disease
-
Rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis and antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis are often associated with reduced levels of EPCs and impaired EPC function
-
In systemic sclerosis, levels of EPCs are increased early in the disease, followed by a progressive decline
-
Multiple mechanisms are involved in EPC dysfunction in rheumatic disease
-
EPC levels can be therapeutically increased using immunosuppressants and, potentially, statins
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Shoenfeld, Y. et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112, 3337–3347 (2005).
Giles, J. T., Post, W., Blumenthal, R. S. & Bathon, J. M. Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2, 320–329 (2006).
Kimhi, O. et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin. Arthritis Rheum. 36, 203–209 (2007).
Pagnoux, C., Chironi, G., Simon, A. & Guillevin, L. Atherosclerosis in ANCA-associated vasculitides. Ann. NY Acad. Sci. 1107, 11–21 (2007).
Westerweel, P. E., Luyten, R. K., Koomans, H. A., Derksen, R. H. & Verhaar, M. C. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum. 56, 1384–1396 (2007).
Eder, L. et al. Subclinical atherosclerosis in psoriatic arthritis: a case–control study. J. Rheumatol. 35, 877–882 (2008).
Braam, B. & Verhaar, M. C. Understanding eNOS for pharmacological modulation of endothelial function: a translational view. Curr. Pharm. Des. 13, 1727–1740 (2007).
Hahn, B. H., Grossman, J., Chen, W. & McMahon, M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J. Autoimmun. 28, 69–75 (2007).
Urbich, C. & Dimmeler, S. Endothelial progenitor cells: characterization and role in vascular biology. Circ. Res. 95, 343–353 (2004).
Schmidt-Lucke, C. et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111, 2981–2987 (2005).
Werner, N. et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353, 999–1007 (2005).
Ruger, B. et al. Endothelial precursor cells in the synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 50, 2157–2166 (2004).
Silverman, M. D., Haas, C. S., Rad, A. M., Arbab, A. S. & Koch, A. E. The role of vascular cell adhesion molecule 1/very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheum. 56, 1817–1826 (2007).
Filer, A. D. et al. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann. Rheum. Dis. 62, 162–167 (2003).
Han, C. et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J. Rheumatol. 33, 2167–2172 (2006).
Gonzalez-Juanatey, C. et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 57, 287–293 (2007).
Belch, J. J., McSwiggan, S. & Lau, C. Macrovascular disease in systemic sclerosis: the tip of an iceberg? Rheumatology (Oxford) 47 (Suppl. 5) v16–v17 (2008).
Gladman, D. D. et al. Cardiovascular morbidity in psoriatic arthritis (PsA). Ann. Rheum. Dis. doi:10.1136/ard.2008.094839 (2008).
Rehman, J., Li, J., Orschell, C. M. & March, K. L. Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107, 1164–1169 (2003).
Urbich, C. et al. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 108, 2511–2516 (2003).
Asahara, T. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964–967 (1997).
Rabelink, T. J., De Boer, H. C., De Koning, E. J. & Van Zonneveld, A. J. Endothelial progenitor cells: more than an inflammatory response? Arterioscler. Thromb. Vasc. Biol. 24, 834–838 (2004).
Urbich, C. & Dimmeler, S. Endothelial progenitor cells functional characterization. Trends Cardiovasc. Med. 14, 318–322 (2004).
Urbich, C. et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J. Mol. Cell. Cardiol. 39, 733–742 (2005).
Distler, J. H. et al. EUSTAR statement and recommendations on endothelial precursor cells. Ann. Rheum. Dis. 68, 163–168 (2009).
Peichev, M. et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood 95, 952–958 (2000).
Shmelkov, S. V. et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J. Clin. Invest. 118, 2111–2120 (2008).
Fadini, G. P. et al. Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis 197, 496–503 (2008).
Westerweel, P. E., Derksen, R. H. & Verhaar, M. C. Comment on: Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology (Oxford) 48, 453 (2009).
Shintani, S. et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103, 2776–2779 (2001).
Eizawa, T. et al. Decrease in circulating endothelial progenitor cells in patients with stable coronary artery disease. Heart 90, 685–686 (2004).
Westerweel, P. E. et al. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. Eur. Heart J. 29, 2808–2817 (2008).
Hill, J. M. et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348, 593–600 (2003).
Loomans, C. J. et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53, 195–199 (2004).
Delva, P. et al. Endothelial progenitor cells in patients with essential hypertension. J. Hypertens. 25, 127–132 (2007).
Westerweel, P. E. et al. End-stage renal disease causes an imbalance between endothelial and smooth muscle progenitor cells. Am. J. Physiol. Renal Physiol. 292, F1132–F1140 (2007).
Herbrig, K., Pistrosch, F., Foerster, S. & Gross, P. Endothelial progenitor cells in chronic renal insufficiency. Kidney Blood Press. Res. 29, 24–31 (2006).
Vasa, M. et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89, E1–E7 (2001).
Heeschen, C. et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 109, 1615–1622 (2004).
Koch, A. E. & Distler, O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res. Ther. 9 (Suppl. 2), S3 (2007).
Ablin, J. N. et al. Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis. Rheumatol. Int. 29, 257–262 (2009).
Egan, C. G., Caporali, F., Garcia-Gonzalez, E., Galeazzi, M. & Sorrentino, V. Endothelial progenitor cells and colony-forming units in rheumatoid arthritis: association with clinical characteristics. Rheumatology (Oxford) 47, 1484–1488 (2008).
Grisar, J. et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111, 204–211 (2005).
Grisar, J. et al. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann. Rheum. Dis. 66, 1284–1288 (2007).
Herbrig, K. et al. Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells. Ann. Rheum. Dis. 65, 157–163 (2006).
Kuwana, M., Okazaki, Y., Yasuoka, H., Kawakami, Y. & Ikeda, Y. Defective vasculogenesis in systemic sclerosis. Lancet 364, 603–610 (2004).
Westerweel, P. E. et al. Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann. Rheum. Dis. 66, 865–870 (2007).
Papadaki, H. A. et al. Increased apoptosis of bone marrow CD34+ cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br. J. Haematol. 115, 167–174 (2001).
Liu, H. et al. Suppression of haematopoiesis by IgG autoantibodies from patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 100, 480–485 (1995).
Tiefenthaler, M. et al. Apoptosis of CD34+ cells after incubation with sera of leukopenic patients with systemic lupus erythematosus. Lupus 12, 471–478 (2003).
Denny, M. F. et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 110, 2907–2915 (2007).
Moonen, J. R. et al. Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Res. Ther. 9, R84 (2007).
Lee, P. Y. et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 56, 3759–3769 (2007).
Grisar, J. et al. Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology (Oxford) 47, 1476–1483 (2008).
Grisar, J. & Smolen, J. S. Comment on: Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells: reply. Rheumatology (Oxford) 48, 453–454 (2009).
Gomer, R. H. Circulating progenitor cells and scleroderma. Curr. Rheumatol. Rep. 10, 183–188 (2008).
Avouac, J. et al. Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann. Rheum. Dis. 67, 1455–1460 (2008).
Del Papa, N. et al. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum. 50, 1296–1304 (2004).
Del Papa, N. et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum. 54, 2605–2615 (2006).
Nevskaya, T. et al. Circulating endothelial progenitor cells in systemic sclerosis: relation to impaired angiogenesis and cardiovascular manifestations. Clin. Exp. Rheumatol. 26, 421–429 (2008).
Zhu, S. et al. Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells. Circulation 118, 2156–2165 (2008).
Holmen, C. et al. Circulating inflammatory endothelial cells contribute to endothelial progenitor cell dysfunction in patients with vasculitis and kidney involvement. J. Am. Soc. Nephrol. 16, 3110–3120 (2005).
de Groot, K. et al. Vascular endothelial damage and repair in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 56, 3847–3853 (2007).
Mayr, F. B. et al. Effects of low dose endotoxemia on endothelial progenitor cells in humans. Atherosclerosis 195, e202–e206 (2007).
Masuda, J. et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with ulcerative colitis. Int. J. Mol. Med. 19, 221–228 (2007).
Kopp, H. G., Avecilla, S. T., Hooper, A. T. & Rafii, S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda) 20, 349–356 (2005).
Yin, T. & Li, L. The stem cell niches in bone. J. Clin. Invest. 116, 1195–1201 (2006).
Kissel, C. K. et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J. Am. Coll. Cardiol. 49, 2341–2349 (2007).
Papadaki, H. A. et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood 99, 1610–1619 (2002).
Aicher, A. et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9, 1370–1376 (2003).
Ozuyaman, B. et al. Nitric oxide differentially regulates proliferation and mobilization of endothelial progenitor cells but not of hematopoietic stem cells. Thromb. Haemost. 94, 770–772 (2005).
Verhaar, M. C. & Rabelink, T. J. Endothelial function: strategies for early intervention. Cardiovasc. Drugs Ther. 12 (Suppl. 1), 125–134 (1998).
Avouac, J. et al. Angiogenesis in systemic sclerosis: Impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions. Arthritis Rheum. 58, 3550–3561 (2008).
Rahimi, N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front. Biosci. 11, 818–829 (2006).
Verma, S. et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109, 2058–2067 (2004).
Imanishi, T., Hano, T., Sawamura, T. & Nishio, I. Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction. Clin. Exp. Pharmacol. Physiol. 31, 407–413 (2004).
Wang, X., Chen, J., Tao, Q., Zhu, J. & Shang, Y. Effects of ox-LDL on number and activity of circulating endothelial progenitor cells. Drug Chem. Toxicol. 27, 243–255 (2004).
Frostegard, J. et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum. 52, 192–200 (2005).
Zhu, J. H. et al. Homocysteine accelerates senescence and reduces proliferation of endothelial progenitor cells. J. Mol. Cell. Cardiol. 40, 648–652 (2006).
Chen, J. Z. et al. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J. Mol. Cell. Cardiol. 36, 233–239 (2004).
Lazzerini, P. E. et al. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun. Rev. 6, 503–509 (2007).
Ablin, J. N. et al. Effect of anti-TNFα treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci. 79, 2364–2369 (2006).
Ronnblom, L., Eloranta, M. L. & Alm, G. V. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum. 54, 408–420 (2006).
Vemulapalli, S. et al. Cell therapy in murine atherosclerosis: in vivo imaging with high-resolution helical SPECT. Radiology 242, 198–207 (2007).
Kurosaka, D. et al. Kinetics of circulating endothelial progenitor cells in mice with type II collagen arthritis. Blood Cells Mol. Dis. 35, 236–240 (2005).
Werner, C., Kamani, C. H., Gensch, C., Bohm, M. & Laufs, U. The peroxisome proliferator-activated receptor-γ agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 56, 2609–2615 (2007).
Bahlmann, F. H. et al. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 45, 526–529 (2005).
Laufs, U. et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109, 220–226 (2004).
Del Papa, N. et al. Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. J. Rheumatol. 35, 1323–1328 (2008).
Choi, J., Kim, J. Y., Kwok, S. K. & Cho, C. S. Endothelial progenitor cell proliferation and differentiation is increased by hydroxychloroquine (conference abstract). Ann. Rheum. Dis. 67, 165 (2008).
Nevskaya, T. et al. Autologous progenitor cell implantation as a novel therapeutic intervention for ischaemic digits in systemic sclerosis. Rheumatology (Oxford) 48, 61–64 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Table 1
Peripheral blood EPC levels in rheumatic diseases compared to healthy controls. (DOC 91 kb)
Rights and permissions
About this article
Cite this article
Westerweel, P., Verhaar, M. Endothelial progenitor cell dysfunction in rheumatic disease. Nat Rev Rheumatol 5, 332–340 (2009). https://doi.org/10.1038/nrrheum.2009.81
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2009.81
This article is cited by
-
Endothelial Progenitor Cells in Autoimmune Disorders
Stem Cell Reviews and Reports (2023)
-
Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment
Arthritis Research & Therapy (2022)
-
Endothelial Progenitor Cell CD34+ and CD133+ Concentrations and Soluble HLA-G Concentrations During Pregnancy and in Cord Blood in Undifferentiated Connective Tissue Diseases Compared to Controls
Reproductive Sciences (2021)
-
Reduced levels of circulating progenitor cells in juvenile idiopathic arthritis are counteracted by anti TNF-α therapy
BMC Musculoskeletal Disorders (2015)
-
Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study
Arthritis Research & Therapy (2015)